U.S. Receives Experimental Smallpox Vaccine

[Guest guest]

" Acambis/Baxter team has once again

demonstrated its ability to manufacture and deliver large quantities of

critical biodefense smallpox vaccines. "

We never thought they'd have a problem manufacturing and delivering

It was the safety issue that concerns us - all vaccines are dangerous,

especially fast produced ones.

So who are these for?

Sheri

U.S. Receives Experimental Smallpox Vaccine

http://www.nti.org/d_newswire/issues/2006_1_4.html#53E4D06E

British drug maker Acambis early last month completed delivery of 500,000

doses of an experimental smallpox vaccine to the U.S. National Institute of

Allergy and Infectious Diseases (see GSN, Nov. 14, 2005).

Delivery of the vaccine, known as MVA3000, fulfills Acambis' end of a 2004

contract with the agency, according to a company press statement.

The vaccine was developed by Acambis and Baxter Healthcare SA, which

produced the vaccines at its facilities.

" With the delivery of 500,000 doses of MVA3000 to the U.S. government, we

have cleared the major hurdle of the NIAID's second contract for MVA

vaccine, " said Acambis CEO Gordon Cameron in the press release. " By

achieving this milestone, the Acambis/Baxter team has once again

demonstrated its ability to manufacture and deliver large quantities of

critical biodefense smallpox vaccines. Our proven manufacturing capability

for MVA3000 can only strengthen the proposal we submitted to the U.S.

government for the manufacture of up to 20 million doses of MVA " (see GSN,

Oct. 4; Acambis press release, Dec. 2).

Randi Airola

517-819-5926